Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning to early utilization. In the fourth quarter of fiscal 2026, Burcon reported revenue of $0.83 million, up from $0.74 million in the prior quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on activity in April and May.
The company completed commissioning and launched commercial production across three protein lines—Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein—during FY26. A new production record was set, with daily output roughly 60% above levels seen from January through March. As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure, rather than from pricing alone.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects spanning pea, canola, and fava applications. Funding supports the Galesburg scale-up: $6.9 million has been completed, with an additional $3.0 million undrawn. Management is targeting $10 million in calendar year 2026 sales.
For the full announcement, including downloadable images and bios, click here.
Stonegate Capital Partners is a capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services for public and private companies.
